Merck & Co. Inc. has had its submission for a more convenient six-week dosing of its blockbuster immunotherapy treatment Keytruda refused by the US Food and Drug Administration.
The regulator has issued a complete response letter (CRL) to the company, which is seeking to introduce the every-six-weeks administration of a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?